Depo-Provera in the treatment of recurrent vulvovaginal candidiasis.
The long-acting injectable progestogen Depo-Provera appears to substantially reduce women's susceptibility to recurrent vulvovaginal candidiasis. Pregnancy and exogenous estrogen appear to counteract this effect of the drug. Evidence was derived from 15 patients studied for up to six years.
D000328:Adult; D002177:Candidiasis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D012008:Recurrence; D014623:Vaginal Diseases / Q000188:drug therapy*; D014845:Vulvar Diseases / Q000188:drug therapy*
D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone